{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T04:22:34Z","timestamp":1793161354041,"version":"4.5.0"},"reference-count":50,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2024,11,9]],"date-time":"2024-11-09T00:00:00Z","timestamp":1731110400000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,3,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Introduction<\/jats:title>\n                  <jats:p>Hypertrophic cardiomyopathy (HCM) is the most prevalent inherited cardiac disease. The impact of HCM on quality of life (QoL) and societal costs remains poorly understood. This prospective multi-centre burden of disease study estimated QoL and societal costs of genotyped HCM patients and genotype-positive phenotype-negative (G+\/P\u2212) subjects.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods and results<\/jats:title>\n                  <jats:p>Participants were categorized into three groups based on genotype and phenotype: (i) G+\/P\u2212 [left ventricular (LV) wall thickness &amp;lt;13 mm], (ii) non-obstructive HCM [nHCM, LV outflow tract (LVOT) gradient &amp;lt;30 mmHg], and (iii) obstructive HCM (oHCM, LVOT gradient \u226530 mmHg). We assessed QoL with EQ-5D-5L and Kansas City Cardiomyopathy Questionnaires (KCCQ). Societal costs were measured using medical consumption (Medical Consumption Questionnaire) and productivity cost (iMTA Productivity Cost Questionnaire) questionnaires. We performed subanalyses within three age groups: &amp;lt;40, 40\u201359, and \u226560 years. From three Dutch hospitals, 506 subjects were enrolled (84 G+\/P\u2212, 313 nHCM, 109 oHCM; median age 59 years, 39% female). HCM (both nHCM and oHCM) patients reported reduced QoL vs. G+\/P\u2212 subjects (KCCQ: 88 vs. 98, EQ-5D-5L: 0.88 vs. 0.96; both P\u00a0&amp;lt;\u00a00.001). oHCM patients reported lower KCCQ scores than nHCM patients (83 vs. 89, P\u00a0=\u00a00.036). Societal costs were significantly higher in HCM patients (\u20ac19,035\/year vs. \u20ac7385\/year) compared with G+\/P\u2212 controls, mainly explained by higher healthcare costs and productivity losses. Being symptomatic and of younger age (&amp;lt;60 years) particularly led to decreased QoL and increased costs.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>HCM is associated with decreased QoL and increased societal costs, especially in younger and symptomatic patients. oHCM patients were more frequently symptomatic than nHCM patients. This study highlights the substantial disease burden of HCM and can aid in assessing new therapy cost-effectiveness for HCM in the future.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ehjqcco\/qcae092","type":"journal-article","created":{"date-parts":[[2024,11,9]],"date-time":"2024-11-09T16:06:07Z","timestamp":1731168367000},"page":"174-185","source":"Crossref","is-referenced-by-count":21,"title":["Loss of quality of life and increased societal costs in patients with hypertrophic cardiomyopathy: the AFFECT-HCM study"],"prefix":"10.1093","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6235-016X","authenticated-orcid":false,"given":"Stephan A C","family":"Schoonvelde","sequence":"first","affiliation":[{"name":"Department of Cardiology, Erasmus MC, Cardiovascular Institute, Thorax Center , Dr. Molewaterplein 40, 3015 GD, Rotterdam ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2608-2900","authenticated-orcid":false,"given":"Isabell","family":"Wiethoff","sequence":"additional","affiliation":[{"name":"Department of Health Services Research, Care and Public Health Research Institute (CAPHRI), Maastricht University , 6229 ER, Maastricht ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2634-4667","authenticated-orcid":false,"given":"Peter-Paul","family":"Zwetsloot","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Erasmus MC, Cardiovascular Institute, Thorax Center , Dr. Molewaterplein 40, 3015 GD, Rotterdam ,","place":["The Netherlands"]},{"name":"Netherlands Heart Institute , 3511 EP, Utrecht ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3315-2006","authenticated-orcid":false,"given":"Alexander","family":"Hirsch","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Erasmus MC, Cardiovascular Institute, Thorax Center , Dr. Molewaterplein 40, 3015 GD, Rotterdam ,","place":["The Netherlands"]},{"name":"Department of Radiology and Nuclear Medicine, Erasmus MC , 3015 GD, Rotterdam ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5457-3010","authenticated-orcid":false,"given":"Christian","family":"Knackstedt","sequence":"additional","affiliation":[{"name":"Department of Cardiology and Cardiovascular Research Institute Maastricht (CARIM), Maastricht University Medical Center+ , 6229 HX, Maastricht ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2781-0145","authenticated-orcid":false,"given":"Tjeerd","family":"Germans","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Northwest Clinics , 1815 JD, Alkmaar ,","place":["the Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8165-6631","authenticated-orcid":false,"given":"Maurits","family":"Sikking","sequence":"additional","affiliation":[{"name":"Department of Cardiology and Cardiovascular Research Institute Maastricht (CARIM), Maastricht University Medical Center+ , 6229 HX, Maastricht ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6424-0754","authenticated-orcid":false,"given":"Arend F L","family":"Schinkel","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Erasmus MC, Cardiovascular Institute, Thorax Center , Dr. Molewaterplein 40, 3015 GD, Rotterdam ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marjon A","family":"van Slegtenhorst","sequence":"additional","affiliation":[{"name":"Department of Clinical Genetics, Erasmus MC , 3015 GD, Rotterdam ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0340-3433","authenticated-orcid":false,"given":"Judith M A","family":"Verhagen","sequence":"additional","affiliation":[{"name":"Department of Clinical Genetics, Erasmus MC , 3015 GD, Rotterdam ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4775-9140","authenticated-orcid":false,"given":"Rudolf A","family":"de Boer","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Erasmus MC, Cardiovascular Institute, Thorax Center , Dr. Molewaterplein 40, 3015 GD, Rotterdam ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1026-570X","authenticated-orcid":false,"given":"Silvia M A A","family":"Evers","sequence":"additional","affiliation":[{"name":"Department of Health Services Research, Care and Public Health Research Institute (CAPHRI), Maastricht University , 6229 ER, Maastricht ,","place":["The Netherlands"]},{"name":"Trimbos Institute, Netherlands Institute of Mental Health and Addiction, Centre for Economic Evaluation , 3521 VS, Utrecht ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Micka\u00ebl","family":"Hiligsmann","sequence":"additional","affiliation":[{"name":"Department of Health Services Research, Care and Public Health Research Institute (CAPHRI), Maastricht University , 6229 ER, Maastricht ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6432-0431","authenticated-orcid":false,"given":"Michelle","family":"Michels","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Erasmus MC, Cardiovascular Institute, Thorax Center , Dr. Molewaterplein 40, 3015 GD, Rotterdam ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,11,8]]},"reference":[{"key":"2025030423575595000_bib1","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1161\/CIRCRESAHA.117.311059","article-title":"Hypertrophic cardiomyopathy: genetics, pathogenesis, clinical manifestations, diagnosis, and therapy","volume":"121","author":"Marian","year":"2017","journal-title":"Circ Res"},{"key":"2025030423575595000_bib2","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1161\/01.CIR.92.4.785","article-title":"Prevalence of hypertrophic cardiomyopathy in a general population of young adults: echocardiographic analysis of 4111 subjects in the CARDIA study","volume":"92","author":"Maron","year":"1995","journal-title":"Circulation"},{"key":"2025030423575595000_bib3","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.amjmed.2003.05.009","article-title":"Prevalence of idiopathic hypertrophic cardiomyopathy in China: a population-based echocardiographic analysis of 8080 adults","volume":"116","author":"Zou","year":"2004","journal-title":"Am J Med"},{"key":"2025030423575595000_bib4","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1161\/CIRCULATIONAHA.117.033200","article-title":"Genotype and lifetime burden of disease in hypertrophic cardiomyopathy: insights from the Sarcomeric Human Cardiomyopathy Registry (SHaRe)","volume":"138","author":"Ho","year":"2018","journal-title":"Circulation"},{"key":"2025030423575595000_bib5","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1056\/NEJMra1710575","article-title":"Clinical course and management of hypertrophic cardiomyopathy","volume":"379","author":"Maron","year":"2018","journal-title":"N Engl J Med"},{"key":"2025030423575595000_bib6","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1080\/17431380410032526","article-title":"Family and population strategies for screening and counselling of inherited cardiac arrhythmias","volume":"36","author":"Van Langen","year":"2004","journal-title":"Ann Med"},{"key":"2025030423575595000_bib7","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1136\/hrt.78.2.182","article-title":"Health related quality of life and psychological wellbeing in patients with hypertrophic cardiomyopathy","volume":"78","author":"Cox","year":"1997","journal-title":"Heart"},{"key":"2025030423575595000_bib8","doi-asserted-by":"crossref","first-page":"327","DOI":"10.3350\/cmh.2014.20.4.327","article-title":"Cost-of-illness studies: concepts, scopes, and methods","volume":"20","author":"Jo","year":"2014","journal-title":"Clin Mol Hepatol"},{"key":"2025030423575595000_bib9","doi-asserted-by":"crossref","first-page":"653","DOI":"10.2165\/11588380-000000000-00000","article-title":"Cost-of-illness studies: a guide to critical evaluation","volume":"29","author":"Larg","year":"2011","journal-title":"Pharmacoeconomics"},{"key":"2025030423575595000_bib10","doi-asserted-by":"crossref","first-page":"100089","DOI":"10.1016\/j.ahjo.2022.100089","article-title":"Healthcare resource utilization and cost of obstructive hypertrophic cardiomyopathy in a US population","volume":"13","author":"Butzner","year":"2022","journal-title":"Am Heart J Plus Card Res Pract"},{"key":"2025030423575595000_bib11","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1080\/13696998.2021.1978242","article-title":"Clinical and economic burden of obstructive hypertrophic cardiomyopathy in the United States","volume":"24","author":"Jain","year":"2021","journal-title":"J Med Econ"},{"key":"2025030423575595000_bib12","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1016\/j.amjcard.2016.04.059","article-title":"Hypertrophic obstructive cardiomyopathy and the cost of treatment","volume":"117","author":"Jan","year":"2016","journal-title":"Am J Cardiol"},{"key":"2025030423575595000_bib13","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1007\/s12471-023-01776-1","article-title":"A systematic literature review of economic evaluations and cost-of-illness studies of inherited cardiomyopathies","volume":"31","author":"Wiethoff","year":"2023","journal-title":"Neth Heart J"},{"key":"2025030423575595000_bib14","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1007\/s12471-022-01753-0","article-title":"Quality of life and societal costs in hypertrophic cardiomyopathy: protocol of the AFFECT-HCM study","volume":"31","author":"Schoonvelde","year":"2023","journal-title":"Neth Heart J"},{"key":"2025030423575595000_bib15","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/gim.2015.30","article-title":"Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology","volume":"17","author":"Richards","year":"2015","journal-title":"Genet Med"},{"key":"2025030423575595000_bib16","doi-asserted-by":"crossref","first-page":"3503","DOI":"10.1093\/eurheartj\/ehad194","article-title":"2023 ESC Guidelines for the management of cardiomyopathies: developed by the task force on the management of cardiomyopathies of the European Society of Cardiology (ESC)","volume":"44","author":"Arbelo","year":"2023","journal-title":"Eur Heart J"},{"key":"2025030423575595000_bib17","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.jcmg.2023.07.012","article-title":"Improved diagnostic criteria for apical hypertrophic cardiomyopathy","volume":"17","author":"Hughes","year":"2024","journal-title":"JACC Cardiovasc Imaging"},{"key":"2025030423575595000_bib18","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1093\/eurheartj\/eht439","article-title":"A novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy (HCM risk-SCD)","volume":"35","author":"O'Mahony","year":"2014","journal-title":"Eur Heart J"},{"key":"2025030423575595000_bib19","article-title":"Basic information on how to use the EQ-5D-5L instrument: EuroQoL Research Foundation","author":"EQ-5D-5L User Guide","year":"2019"},{"key":"2025030423575595000_bib20","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.jval.2016.01.003","article-title":"Dutch tariff for the five-level version of EQ-5D","volume":"19","author":"Versteegh","year":"2016","journal-title":"Value Health"},{"key":"2025030423575595000_bib21","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1016\/j.jacc.2020.09.542","article-title":"Interpreting the Kansas City Cardiomyopathy Questionnaire in clinical trials and clinical care: JACC state-of-the-art review","volume":"76","author":"Spertus","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2025030423575595000_bib22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12955-020-01604-9","article-title":"Quality of life status determinants in hypertrophic cardiomyopathy as evaluated by the Kansas City Cardiomyopathy Questionnaire","volume":"18","author":"Capota","year":"2020","journal-title":"Health Qual Life Outcomes"},{"key":"2025030423575595000_bib23","first-page":"531","article-title":"Validation of the Kansas City cardiomyopathy Questionnaire in symptomatic obstructive hypertrophic cardiomyopathy","volume":"10","author":"Nassif","year":"2022","journal-title":"Heart Failure"},{"key":"2025030423575595000_bib24","volume-title":"Manual iMTA Medical Cost Questionnaire (iMCQ)","author":"iMTA Productivity and Health Research Group","year":"2018"},{"key":"2025030423575595000_bib25","volume-title":"Methods for the Economic Evaluation of Health Care Programmes","author":"Drummond","year":"2015"},{"key":"2025030423575595000_bib26","volume-title":"Farmacotherapeutisch Kompas","year":"2024"},{"key":"2025030423575595000_bib27","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.jhealeco.2014.01.007","article-title":"Forgetting to remember or remembering to forget: a study of the recall period length in health care survey questions","volume":"35","author":"Kjellsson","year":"2014","journal-title":"J Health Econ"},{"key":"2025030423575595000_bib28","volume-title":"Richtlijn voor Het Uivoeren van Economische Evaluaties in de Gezondheidszorg","author":"Hakkaart-van Roijen LP, Stijn. Kanters, Tim","year":"2024"},{"key":"2025030423575595000_bib29","year":"2016"},{"key":"2025030423575595000_bib30","volume-title":"Centraal Bureau voor de Statistiek","author":"Consumer Prices","year":"2023"},{"key":"2025030423575595000_bib31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12874-018-0657-9","article-title":"Methods of sample size calculation in descriptive retrospective burden of illness studies","volume":"19","author":"Johnston","year":"2019","journal-title":"BMC Med Res Methodol"},{"key":"2025030423575595000_bib32","doi-asserted-by":"crossref","first-page":"67","DOI":"10.4103\/aca.ACA_157_18","article-title":"Descriptive statistics and normality tests for statistical data","volume":"22","author":"Mishra","year":"2019","journal-title":"Ann Card Anaesth"},{"key":"2025030423575595000_bib33","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.jvs.2009.08.042","article-title":"Challenges in analysis and interpretation of cost data in vascular surgery","volume":"51","author":"Mani","year":"2010","journal-title":"J Vasc Surg"},{"key":"2025030423575595000_bib34","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1136\/bmj.320.7243.1197","article-title":"How should cost data in pragmatic randomised trials be analysed?","volume":"320","author":"Thompson","year":"2000","journal-title":"BMJ"},{"key":"2025030423575595000_bib35","article-title":"[Absenteeism]: Central Bureau of Statistics Netherlands","author":"Ziekteverzuim"},{"key":"2025030423575595000_bib36","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1002\/ajmg.a.32710","article-title":"Quality of life and psychological distress in hypertrophic cardiomyopathy mutation carriers: a cross-sectional cohort study","volume":"149","author":"Christiaans","year":"2009","journal-title":"Am J Med Genet A"},{"key":"2025030423575595000_bib37","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1093\/ehjqcco\/qcad056","article-title":"Quality of life and societal costs in patients with dilated cardiomyopathy","volume":"10","author":"Wiethoff","year":"2024","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"key":"2025030423575595000_bib38","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.jacc.2005.04.043","article-title":"Gender-related differences in the clinical presentation and outcome of hypertrophic cardiomyopathy","volume":"46","author":"Olivotto","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"2025030423575595000_bib39","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1046\/j.1525-1497.2001.016004266.x","article-title":"Somatic symptom reporting in women and men","volume":"16","author":"Barsky","year":"2001","journal-title":"J Gen Intern Med"},{"key":"2025030423575595000_bib40","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1097\/00006842-199803000-00006","article-title":"Gender differences in the reporting of physical and somatoform symptoms","volume":"60","author":"Kroenke","year":"1998","journal-title":"Psychosom Med"},{"key":"2025030423575595000_bib41","doi-asserted-by":"crossref","first-page":"e005820","DOI":"10.1161\/CIRCEP.117.005820","article-title":"Clinical course and quality of life in high-risk patients with hypertrophic cardiomyopathy and implantable cardioverter-defibrillators","volume":"11","author":"Maron","year":"2018","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"2025030423575595000_bib42","doi-asserted-by":"crossref","first-page":"2467","DOI":"10.1016\/S0140-6736(21)00763-7","article-title":"Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): health status analysis of a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"397","author":"Spertus","year":"2021","journal-title":"Lancet"},{"key":"2025030423575595000_bib43","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1056\/NEJMoa2401424","article-title":"Aficamten for symptomatic obstructive hypertrophic cardiomyopathy","volume":"390","author":"Maron","year":"2024","journal-title":"N Engl J Med"},{"key":"2025030423575595000_bib44","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1080\/13696998.2021.2011301","article-title":"Assessing health-related quality-of-life in patients with symptomatic obstructive hypertrophic cardiomyopathy: EQ-5D-based utilities in the EXPLORER-HCM trial","volume":"25","author":"Xie","year":"2022","journal-title":"J Med Econ"},{"key":"2025030423575595000_bib45","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1038\/s41569-021-00566-9","article-title":"Towards precision medicine in heart failure","volume":"18","author":"Weldy","year":"2021","journal-title":"Nat Rev Cardiol"},{"key":"2025030423575595000_bib46","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(20)31792-X","article-title":"Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"396","author":"Olivotto","year":"2020","journal-title":"Lancet"},{"key":"2025030423575595000_bib47","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1002\/ejhf.1715","article-title":"Hypertrophic cardiomyopathy: the future of treatment","volume":"22","author":"Tuohy","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2025030423575595000_bib48","article-title":"A study of mavacamten in non-obstructive hypertrophic cardiomyopathy (ODYSSEY-HCM)"},{"key":"2025030423575595000_bib49","article-title":"Phase 3 trial to evaluate the efficacy and safety of aficamten compared to placebo in adults with symptomatic nHCM (ACACIA-HCM)"},{"key":"2025030423575595000_bib50","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.jclinepi.2015.09.019","article-title":"The exchangeability of self-reports and administrative health care resource use measurements: assessement of the methodological reporting quality","volume":"74","author":"Noben","year":"2016","journal-title":"J Clin Epidemiol"}],"container-title":["European Heart Journal - Quality of Care and Clinical Outcomes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ehjqcco\/advance-article-pdf\/doi\/10.1093\/ehjqcco\/qcae092\/60878717\/qcae092.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjqcco\/article-pdf\/11\/2\/174\/60878717\/qcae092.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjqcco\/article-pdf\/11\/2\/174\/60878717\/qcae092.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T23:58:21Z","timestamp":1741132701000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ehjqcco\/article\/11\/2\/174\/7888906"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,8]]},"references-count":50,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,11,8]]},"published-print":{"date-parts":[[2025,3,3]]}},"URL":"https:\/\/doi.org\/10.1093\/ehjqcco\/qcae092","relation":{},"ISSN":["2058-5225","2058-1742"],"issn-type":[{"value":"2058-5225","type":"print"},{"value":"2058-1742","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,3]]},"published":{"date-parts":[[2024,11,8]]}}}